US Patent

US7875630 — Process salts compositions and use

Composition of Matter · Assigned to Glaxo Group Ltd · Expires 2027-02-14 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a novel process for preparing pleuromutilin derivatives, including a specific salt of the active substance in Altabax.

USPTO Abstract

The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.

Drugs covered by this patent

Patent Metadata

Patent number
US7875630
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-02-14
Drug substance claim
Yes
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.